Risks

Negative interest coverage and a 1.49 current ratio indicate limited earnings support for obligations, leaving TOMZ more exposed than better-capitalized medtech peers.

A 228-day cash conversion cycle, driven by 299 days of inventory, ties up working capital and weakens flexibility versus faster-turning device peers.

Days sales outstanding near 100 and payables stretched to 170 days suggest collection and supplier timing pressure, increasing liquidity strain relative to peers.

Net debt to EBITDA is negative because EBITDA is weak, so leverage metrics provide little cushion if demand softens versus profitable peers.

Opportunities

If inventory normalizes, TOMZ could release meaningful working capital, improving cash generation more than peers with already efficient cycles.

A 0.73 quick ratio still provides some near-term liquidity, giving TOMZ more room than weaker microcap peers to bridge operating volatility.

Negative net debt to EBITDA implies limited balance-sheet debt burden, so any margin recovery could translate faster into flexibility than for levered peers.

Overall Score

TOMZ’s forward positioning is constrained by weak coverage, slow working-capital turnover, and liquidity pressure, while modest balance-sheet flexibility and inventory normalization offer limited upside versus peers.